Cargando…
Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy
Risk assessment for natalizumab-associated progressive multifocal leukoencephalopathy (Nat-PML) comprises the anti-JC virus (JCV) antibody index (AI). The anti-JCV AI was longitudinally determined in a natalizumab-treated MS cohort (Nat-MS, n = 468) and samples of Nat-PML patients (n = 15). In Nat-M...
Autores principales: | Salmen, A., von Ahsen, N., Trampe, A.K., Hoepner, R., Plavina, T., Subramanyam, M., Kuesters, G., Gold, R., Chan, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433507/ https://www.ncbi.nlm.nih.gov/pubmed/28607714 http://dx.doi.org/10.1177/2055217316630008 |
Ejemplares similares
-
Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study
por: Hegen, Harald, et al.
Publicado: (2017) -
Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis
por: Hoepner, Robert, et al.
Publicado: (2015) -
Anti-JCV antibody index does not change during ocrelizumab-treatment
por: Rempe, Torge, et al.
Publicado: (2020) -
AIDS-related progressive multifocal leukoencephalopathy
por: Abrão, Carolina de Oliveira, et al.
Publicado: (2020) -
Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
por: Schwab, Nicholas, et al.
Publicado: (2016)